Nearly 600 Risperdal lawsuits have been filed against drug manufacturer Janssen Pharmaceuticals and its parent company Johnson & Johnson, according to a release from Psychiatric News. The lawsuits allege that the companies withheld information about Risperdal side effects, including male breast tissue growth, or gynecomastia.
Johnson & Johnson has reportedly reached a Risperdal settlement in as many as 80 of the lawsuits in Philadelphia. The company is expected to face more lawsuits as male adolescents and young boys who were given Risperdal come forward with claims of breast tissue growth.
Risperdal is an antipsychotic drug that is used to treat symptoms of bipolar disorder and attention deficit hyperactivity disorder (ADHD), but has also been given to young patients for unapproved uses. Recent studies have found that the drug increases levels of a hormone known as prolactin indefinitely, which can lead to gynecomastia and other side effects.